Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma

被引：316

作者：

Cheson, Bruce D. ^{[1
]}

Leonard, John P. ^{[2
]}

机构：

[1] Georgetown Univ Hosp, Div Hematol Oncol, Washington, DC 20007 USA

[2] Weill Cornell Med Coll, Ctr Lymphoma & Myeloma, New York, NY USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2008年 / 359卷 / 06期

关键词：

D O I：

10.1056/NEJMra0708875

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

[No abstract available]

引用

收藏

页码：613 / 626

页数：14

相关论文

共 117 条

[1]

Advani R, 2006, BLOOD, V108, p209A

[2]

Alas S, 2001, CANCER RES, V61, P5137

[3]

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma [J].

Ansell, SM ;

Ristow, KM ;

Habermann, TM ;

Wiseman, GA ;

Witzig, TE .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3885-3890

[4]

New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].

Armitage, JO ;

Weisenburger, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795

[5]

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab [J].

Bennett, JM ;

Kaminski, MS ;

Leonard, JP ;

Vose, JM ;

Zelenetz, AD ;

Knox, SJ ;

Horning, S ;

Press, OW ;

Radford, JA ;

Kroll, SM ;

Capizzi, RL .

BLOOD, 2005, 105 (12) :4576-4582

[6]

Variation in gene expression patterns in follicular lymphoma and the response to rituximab [J].

Bohen, SP ;

Troyanskaya, OG ;

Alter, O ;

Warnke, R ;

Botstein, D ;

Brown, PO ;

Levy, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1926-1930

[7]

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].

Byrd, JC ;

Rai, K ;

Peterson, BL ;

Appelbaum, FR ;

Morrison, VA ;

Kolitz, JE ;

Shepherd, L ;

Hines, JD ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2005, 105 (01) :49-53

[8]

Comparison of results from a phase 1/2 study of lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. [J].

Byrd, John C. ;

Castro, Januario ;

O'Brien, Susan ;

Flinn, Ian W. ;

Forero-Torres, Andres ;

Kipps, Thomas J. ;

Heerema, Nyla A. ;

Lin, Thomas ;

Kheoh, Thian ;

Wynne, Dee ;

Molina, Arturo .

BLOOD, 2006, 108 (11) :14A-14A

[9]

Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia [J].

Byrd, John C. ;

O'Brien, Susan ;

Flinn, Ian W. ;

Kipps, Thomas J. ;

Weiss, Mark ;

Rai, Kanti ;

Lin, Thomas S. ;

Woodworth, James ;

Wynne, Dee ;

Reid, Jennifer ;

Molina, Arturo ;

Leigh, Bryan ;

Harris, Sarah .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4448-4455

[10]

From the bench to the bedside: ways to improve rituximab efficacy [J].

Cartron, G ;

Watier, H ;

Golay, J ;

Solal-Celigny, P .

BLOOD, 2004, 104 (09) :2635-2642

← 1 2 3 4 5 6 7 8 9 10 →